Inventor · disambiguated record
Serengulam V. Govindan
Also filed as: GOVINDAN SERENGULAM · GOVINDAN SERENGULAM V
112 granted patents·30 pending applications·2,493 citations·filing 1995–2025
99Inventor score
Top patents by PatentIndex Score
142 records- 0199US11541047B2Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicityIMMUNOMEDICS INC·Filed 2020·Granted Jan 3, 2023·5 cites·16 claims
- 0299US9492566B2Antibody-drug conjugates and uses thereofIMMUNOMEDICS INC·Filed 2015·Granted Nov 15, 2016·61 cites·22 claims
- 0399US8425912B2Immunoconjugates with an intracellularly-cleavable linkageGOVINDAN SERENGULAM V·Filed 2012·Granted Apr 23, 2013·82 cites·16 claims
- 0499US8420086B2Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseasesGOVINDAN SERENGULAM V·Filed 2011·Granted Apr 16, 2013·68 cites·43 claims
- 0599US8268317B2Camptothecin-binding moiety conjugatesGOVINDAN SERENGULAM V·Filed 2009·Granted Sep 18, 2012·82 cites·34 claims
- 0699US8268319B2Immunoconjugates with an intracellularly-cleavable linkageGOVINDAN SERENGULAM V·Filed 2009·Granted Sep 18, 2012·79 cites·17 claims
- 0799US8080250B1Immunoconjugates with an intracellularly-cleavable linkageGOVINDAN SERENGULAM V·Filed 2011·Granted Dec 20, 2011·106 cites·15 claims
- 0899US7999083B2Immunoconjugates with an intracellularly-cleavable linkageIMMUNOMEDICS INC·Filed 2009·Granted Aug 16, 2011·184 cites·13 claims
- 0999US7591994B2Camptothecin-binding moiety conjugatesIMMUNOMEDICS INC·Filed 2008·Granted Sep 22, 2009·129 cites·14 claims
- 1098US11116846B2Antibody-drug conjugates and uses thereofIMMUNOMEDICS INC·Filed 2020·Granted Sep 14, 2021·8 cites·16 claims
- 1198US11020489B2Immunoconjugates with an intracellularly-cleavable linkageIMMUNOMEDICS INC·Filed 2020·Granted Jun 1, 2021·4 cites·16 claims
- 1298US10849986B2Antibody-drug conjugates and uses thereofIMMUNOMEDICS INC·Filed 2020·Granted Dec 1, 2020·5 cites·15 claims
- 1398US10682347B2Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicityIMMUNOMEDICS INC·Filed 2018·Granted Jun 16, 2020·11 cites·18 claims
- 1498US10137196B2Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicityIMMUNOMEDICS INC·Filed 2016·Granted Nov 27, 2018·18 cites·20 claims
- 1598US9138485B2Immunoconjugates with an intracellularly-cleavable linkageIMMUNOMEDICS INC·Filed 2014·Granted Sep 22, 2015·32 cites·15 claims
- 1698US9028833B2Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicityIMMUNOMEDICS INC·Filed 2013·Granted May 12, 2015·48 cites·22 claims
- 1798US8759496B2Immunoconjugates with an intracellularly-cleavable linkageIMMUNOMEDICS INC·Filed 2012·Granted Jun 24, 2014·38 cites·16 claims
- 1898US8435529B2Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapyGOVINDAN SERENGULAM V·Filed 2010·Granted May 7, 2013·30 cites·19 claims
- 1998US8084583B2RS7 antibodiesGOVINDAN SERENGULAM V·Filed 2009·Granted Dec 27, 2011·44 cites·28 claims
- 2098US7585491B2Immunoconjugates with an intracellularly-cleavable linkageIMMUNOMEDICS INC·Filed 2003·Granted Sep 8, 2009·148 cites·40 claims
- 2198US7238785B2RS7 antibodiesIMMUNOMEDICS INC·Filed 2003·Granted Jul 3, 2007·237 cites·8 claims
- 2297US10653793B2Antibody-drug conjugates and uses thereofIMMUNOMEDICS INC·Filed 2018·Granted May 19, 2020·8 cites·11 claims
- 2397US10130626B2Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicityIMMUNOMEDICS INC·Filed 2016·Granted Nov 20, 2018·18 cites·16 claims
- 2497US10130718B2Antibody-drug conjugates and uses thereofIMMUNOMEDICS INC·Filed 2016·Granted Nov 20, 2018·12 cites·10 claims
- 2597US10064957B2Immunoconjugates with an intracellularly-cleavable linkageIMMUNOMEDICS INC·Filed 2017·Granted Sep 4, 2018·14 cites·24 claims
- 2697US9629926B2Antibody-SN-38 immunoconjugates with a CL2A linkerIMMUNOMEDICS INC·Filed 2016·Granted Apr 25, 2017·21 cites·21 claims
- 2797US9480756B2Immunoconjugates with an intracellularly-cleavable linkageIMMUNOMEDICS INC·Filed 2016·Granted Nov 1, 2016·13 cites·28 claims
- 2897US9375489B2Antibody-SN-38 immunoconjugates with a CL2A linkerIMMUNOMEDICS INC·Filed 2015·Granted Jun 28, 2016·21 cites·19 claims
- 2997US9238084B2Anti-mucin antibodies for early detection and treatment of pancreatic cancerIMMUNOMEDICS INC·Filed 2015·Granted Jan 19, 2016·36 cites·22 claims
- 3097US9198978B2Immunoconjugates with an intracellularly-cleavable linkageIMMUNOMEDICS INC·Filed 2015·Granted Dec 1, 2015·20 cites·16 claims
- 3197US9102735B2Immunoconjugates with an intracellularly-cleavable linkageIMMUNOMEDICS INC·Filed 2013·Granted Aug 11, 2015·27 cites·15 claims
- 3297US8741300B2Immunoconjugates with an intracellularly-cleavable linkageGOVINDAN SERENGULAM V·Filed 2011·Granted Jun 3, 2014·25 cites·9 claims
- 3396US10918721B2Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicityIMMUNOMEDICS INC·Filed 2018·Granted Feb 16, 2021·7 cites·20 claims
- 3496US9522959B2Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicityIMMUNOMEDICS INC·Filed 2015·Granted Dec 20, 2016·13 cites·19 claims
- 3596US9493573B2Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicityIMMUNOMEDICS INC·Filed 2015·Granted Nov 15, 2016·12 cites·23 claims
- 3696US9345783B2Immunoconjugates with an intracellularly-cleavable linkageIMMUNOMEDICS INC·Filed 2015·Granted May 24, 2016·12 cites·17 claims
- 3796US9233172B2Immunoconjugates with an intracellularly-cleavable linkageIMMUNOMEDICS INC·Filed 2015·Granted Jan 12, 2016·12 cites·16 claims
- 3896US8999344B2Immunoconjugates with an intracellularly-cleavable linkageIMMUNOMEDICS INC·Filed 2014·Granted Apr 7, 2015·19 cites·18 claims
- 3996US8877901B2Camptothecin-binding moiety conjugatesGOVINDAN SERENGULAM V·Filed 2006·Granted Nov 4, 2014·50 cites·31 claims
- 4096US7517964B2RS7 antibodiesIMMUNOMEDICS INC·Filed 2007·Granted Apr 14, 2009·68 cites·14 claims
- 4195US11192955B2Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitorsIMMUNOMEDICS INC·Filed 2019·Granted Dec 7, 2021·4 cites·26 claims
- 4295US10206918B2Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancersIMMUNOMEDICS INC·Filed 2017·Granted Feb 19, 2019·10 cites·23 claims
- 4395US10143756B2Antibody-SN-38 immunoconjugates with a CL2A linkerIMMUNOMEDICS INC·Filed 2018·Granted Dec 4, 2018·8 cites·14 claims
- 4495US9107960B2Antibody-SN-38 immunoconjugates with a CL2A linkerIMMUNOMEDICS INC·Filed 2014·Granted Aug 18, 2015·16 cites·22 claims
- 4595US8877202B2Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancerIMMUNOMEDICS INC·Filed 2014·Granted Nov 4, 2014·27 cites·45 claims
- 4695US8834886B2Camptothecin-binding moiety conjugatesIMMUNOMEDICS INC·Filed 2013·Granted Sep 16, 2014·18 cites·31 claims
- 4795US8758752B2RS7 antibodiesIMMUNOMEDICS INC·Filed 2013·Granted Jun 24, 2014·16 cites·17 claims
- 4895US8617558B2Camptothecin-binding moiety conjugatesGOVINDAN SERENGULAM V·Filed 2012·Granted Dec 31, 2013·12 cites·24 claims
- 4994US10266605B2Efficacy of anti-trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitorsIMMUNOMEDICS INC·Filed 2017·Granted Apr 23, 2019·9 cites·25 claims
- 5094US10265414B2Immunoconjugates with an intracellularly-cleavable linkageIMMUNOMEDICS INC·Filed 2018·Granted Apr 23, 2019·6 cites·24 claims
Showing the top 50 of 142 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Serengulam V. Govindan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →